Cargando…

Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis

Despite the enormous morbidity attributed to schistosomiasis, there is still no vaccine to combat the disease for the hundreds of millions of infected people. The anthelmintic drug, praziquantel, is the mainstay treatment option, although its molecular mechanism of action remains poorly defined. Pra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pearson, Mark S., Tedla, Bemnet A., Becker, Luke, Nakajima, Rie, Jasinskas, Al, Mduluza, Takafira, Mutapi, Francisca, Oeuvray, Claude, Greco, Beatrice, Sotillo, Javier, Felgner, Philip L., Loukas, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186320/ https://www.ncbi.nlm.nih.gov/pubmed/34113343 http://dx.doi.org/10.3389/fimmu.2021.663041

Ejemplares similares

Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study
por: Pearson, Mark S, et al.
Publicado: (2021)

Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and Primary School-Aged Children
por: Wami, Welcome M., et al.
Publicado: (2016)

Pharmacogenetics of Praziquantel Metabolism: Evaluating the Cytochrome P450 Genes of Zimbabwean Patients During a Schistosomiasis Treatment
por: Zdesenko, Grace, et al.
Publicado: (2022)

Putting the treatment of paediatric schistosomiasis into context
por: Mduluza, Takafira, et al.
Publicado: (2017)

Identifying and Evaluating Field Indicators of Urogenital Schistosomiasis-Related Morbidity in Preschool-Aged Children
por: Wami, Welcome M., et al.
Publicado: (2015)

Of Monkeys and Men: Immunomic Profiling of Sera from Humans and Non-Human Primates Resistant to Schistosomiasis Reveals Novel Potential Vaccine Candidates
por: Pearson, Mark S., et al.
Publicado: (2015)

Schistosomiasis vaccine discovery using immunomics
por: Driguez, Patrick, et al.
Publicado: (2010)

Decrease in Seminal HIV-1 RNA Load After Praziquantel Treatment of Urogenital Schistosomiasis Coinfection in HIV-Positive Men—An Observational Study
por: Midzi, Nicholas, et al.
Publicado: (2017)

Characterisation of tetraspanins from Schistosoma haematobium and evaluation of their potential as novel diagnostic markers
por: Mekonnen, Gebeyaw G., et al.
Publicado: (2022)

The gut microbiome but not the resistome is associated with urogenital schistosomiasis in preschool-aged children
por: Osakunor, Derick N. M., et al.
Publicado: (2020)

Elevation of C-reactive protein, P-selectin and Resistin as potential inflammatory biomarkers of urogenital Schistosomiasis exposure in preschool children
por: Chimponda, Theresa N., et al.
Publicado: (2019)

Association of schistosomiasis and risk of prostate cancer development in residents of Murehwa rural community, Zimbabwe
por: Choto, Emilia T., et al.
Publicado: (2020)

Schistosoma haematobium Treatment in 1–5 Year Old Children: Safety and Efficacy of the Antihelminthic Drug Praziquantel
por: Mutapi, Francisca, et al.
Publicado: (2011)

Vaccination with Schistosoma mansoni Cholinesterases Reduces the Parasite Burden and Egg Viability in a Mouse Model of Schistosomiasis
por: Tedla, Bemnet A., et al.
Publicado: (2020)

Schistosoma haematobium Extracellular Vesicle Proteins Confer Protection in a Heterologous Model of Schistosomiasis
por: Mekonnen, Gebeyaw G., et al.
Publicado: (2020)

Cytokine Responses to the Anti-schistosome Vaccine Candidate Antigen Glutathione-S-transferase Vary with Host Age and Are Boosted by Praziquantel Treatment
por: Bourke, Claire D., et al.
Publicado: (2014)

Effects of TNF-α and IL-10-819 T>C single nucleotide polymorphisms on urogenital schistosomiasis in preschool children in Zimbabwe
por: Marume, Amos, et al.
Publicado: (2021)

Immunological Consequences of Antihelminthic Treatment in Preschool Children Exposed to Urogenital Schistosome Infection
por: Rujeni, Nadine, et al.
Publicado: (2013)

Explaining Observed Infection and Antibody Age-Profiles in Populations with Urogenital Schistosomiasis
por: Mitchell, Kate M., et al.
Publicado: (2011)

Interleukin-10 and tumour necrosis factor alpha promoter region polymorphisms and susceptibility to urogenital schistosomiasis in young Zimbabwean children living in Schistosoma haematobium endemic regions
por: Marume, Amos, et al.
Publicado: (2020)

Parasitological Observation in Schoolchildren with Urogenital Schistosomiasis Following Treatment with Three Different Brands of Praziquantel
por: Jin, Yan, et al.
Publicado: (2020)

Benefits of annual chemotherapeutic control of schistosomiasis on the development of protective immunity
por: Chisango, Tawanda J., et al.
Publicado: (2019)

Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models
por: Zdesenko, Grace, et al.
Publicado: (2020)

Impact of Annual Praziquantel Treatment on Urogenital Schistosomiasis in a Seasonal Transmission Focus in Central Senegal
por: Senghor, Bruno, et al.
Publicado: (2016)

In-depth proteomic characterization of Schistosoma haematobium: Towards the development of new tools for elimination
por: Sotillo, Javier, et al.
Publicado: (2019)

Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey
por: Knopp, Stefanie, et al.
Publicado: (2016)

Six rounds of annual praziquantel treatment during a national helminth control program significantly reduced schistosome infection and morbidity levels in a cohort of schoolchildren in Zimbabwe
por: Mduluza, Takafira, et al.
Publicado: (2020)

An Immunomics Approach to Schistosome Antigen Discovery: Antibody Signatures of Naturally Resistant and Chronically Infected Individuals from Endemic Areas
por: Gaze, Soraya, et al.
Publicado: (2014)

Integrated Analysis of Innate, Th1, Th2, Th17, and Regulatory Cytokines Identifies Changes in Immune Polarisation Following Treatment of Human Schistosomiasis
por: Bourke, Claire D., et al.
Publicado: (2013)

Epidemiological Interactions between Urogenital and Intestinal Human Schistosomiasis in the Context of Praziquantel Treatment across Three West African Countries
por: Knowles, Sarah C. L., et al.
Publicado: (2015)

Accuracy of the WHO praziquantel dose pole for large-scale community treatment of urogenital schistosomiasis in northern Mozambique: Is it time for an update?
por: Gazzinelli-Guimaraes, Pedro H., et al.
Publicado: (2018)

Persistent Urogenital Schistosomiasis and Its Associated Morbidity in Endemic Communities within Southern Ghana: Suspected Praziquantel Resistance or Reinfection?
por: Tetteh-Quarcoo, Patience B., et al.
Publicado: (2020)

Novel cholinesterase paralogs of Schistosoma mansoni have perceived roles in cholinergic signalling and drug detoxification and are essential for parasite survival
por: Tedla, Bemnet A., et al.
Publicado: (2019)

Association between Micronutrients (Vitamin A, D, Iron) and Schistosome-Specific Cytokine Responses in Zimbabweans Exposed to Schistosoma haematobium
por: Reilly, Liam, et al.
Publicado: (2012)

Dynamics of paediatric urogenital schistosome infection, morbidity and treatment: a longitudinal study among preschool children in Zimbabwe
por: Osakunor, Derick Nii Mensah, et al.
Publicado: (2018)

Exposure, infection, systemic cytokine levels and antibody responses in young children concurrently exposed to schistosomiasis and malaria
por: IMAI, NATSUKO, et al.
Publicado: (2011)

Urogenital schistosomiasis in three different water access in the Senegal river basin: prevalence and monitoring praziquantel efficacy and re-infection levels
por: Senghor, Bruno, et al.
Publicado: (2022)

Regulatory and Activated T Cells in Human Schistosoma haematobium Infections
por: Nausch, Norman, et al.
Publicado: (2011)

Systemic Sclerosis in Zimbabwe: Autoantibody Biomarkers, Clinical, and Laboratory Correlates
por: Sibanda, Elopy N., et al.
Publicado: (2021)

Schistosoma haematobium infection levels determine the effect of praziquantel treatment on anti-schistosome and anti-mite antibodies
por: RUJENI, N, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pd75eo6sj1vndluome549u5d2k